Edition:
United States

Photocure ASA (PHO.OL)

PHO.OL on Oslo Stock Exchange

41.20NOK
10:25am EST
Change (% chg)

kr0.20 (+0.49%)
Prev Close
kr41.00
Open
kr40.40
Day's High
kr41.70
Day's Low
kr39.70
Volume
37,257
Avg. Vol
42,925
52-wk High
kr56.75
52-wk Low
kr32.80

PHO.OL

Chart for PHO.OL

About

Photocure ASA is a Norway-based company active in the pharmaceutical industry. It operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development... (more)

Overall

Beta: 0.35
Market Cap(Mil.): kr883.87
Shares Outstanding(Mil.): 21.56
Dividend: --
Yield (%): --

Financials

  PHO.OL Industry Sector
P/E (TTM): 110.05 29.51 30.38
EPS (TTM): 0.37 -- --
ROI: 3.50 15.44 14.86
ROE: 3.55 16.62 16.28

BRIEF-Photocure: chairperson Bente-Lill Romøren not candidate for re-election

* Chairperson Bente-Lill Romøren not candidate for re-election

10:13am EST

BRIEF-Photocure Q3 EBITDA loss stable at 1.6 million crowns

* Reported a revenue growth of 17 pct to 31.6 million Norwegian crowns ($3.7 million) in Q3 of 2016 (Q3 2015: 27.0 million crowns) for Hexvix/Cysview commercial franchise

Nov 15 2016

BRIEF-Photocure: Hexvix marketing authorization approval in Australia

* Says partner, Juno Pharmaceuticals Pty Ltd, has received marketing authorization approval (MAA) for Hexvix in Australia

Aug 24 2016

BRIEF-Photocure Q2 operating loss widens to NOK 4.4 million

* Q2 sales revenue 34.2 million Norwegian crowns versus 28.9 million crowns year ago

Aug 23 2016

BRIEF-Photocure: Cysview granted FDA approval of new prefilled syringe

* U.S. Food & Drug Administration has granted approval for an improved packaging for Cysview Source text for Eikon:

Aug 11 2016

Earnings vs. Estimates